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Abstract

BACKGROUND & AIMS:
Wilson disease is a severe disorder of copper metabolism caused by mutations in ATP7B, which encodes a copper-transporting ATPase. The disease presents with a variable phenotype that complicates the diagnostic process and treatment.
Little is known about the mechanisms that contribute to the different phenotypes of the disease. METHODS: We analyzed 28 variants of ATP7B from patients with Wilson disease that affected different functional domains; the gene products were expressed using the baculovirus expression system in Sf9 cells. Protein function was analyzed by measuring catalytic activity and copper ( 64 Cu) transport into vesicles. We studied intracellular localization of variants of ATP7B that had measurable transport activities and were tagged with green-fluorescent protein in mammalian cells using confocal laser scanning microscopy.
RESULTS:
Properties of ATP7B variants with pathogenic amino-acid substitution varied greatly even if substitutions were in the same functional domain. Some variants had complete loss of catalytic and transport activity, whereas others lost transport activity but retained phospho-intermediate formation or had partial losses of activity. In mammalian cells, transport-competent variants differed in stability and subcellular localization.
CONCLUSIONS: Variants in ATP7B associated with Wilson disease disrupt the
protein's transport activity, result in its mis-localization, and reduce its stability.
Single assays are insufficient to accurately predict the effects of ATP7B variants the function of its product and development of Wilson disease. These findings will contribute to our understanding of genotype-phenotype correlation and mechanisms of disease pathogenesis.
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Wilson disease (WD) is a hereditary disease due to mutations of the copper transporting Ptype ATPase ATP7B. WD is associated with copper accumulation resulting in liver damage and/or neurologic symptoms 1, 2 . The manifestations of liver disease vary from clinically asymptomatic with only biochemical abnormalities to acute liver failure 3 . Similarly, the spectrum of neurologic manifestations ranges from normal or mild disturbances to a rapid and severe progression of neurologic disability 4 . The mechanisms behind this variability are likely to be complex because even monozygotic twins may have different disease manifestations 5 . Genetic studies showed some association between several mutations and the age of onset/disease severity [6] [7] [8] [9] ; however, robust genotype-phenotype correlation in the case of missense mutations has not so far been found, although complete loss of protein expression due to non-sense mutations is expected to result in a more severe phenotype.
This study focuses on one potential source of phenotypic variability -the effect of mutations in ATP7B on the function of the corresponding Cu-transporting Wilson ATPase.
To date, more than 500 different mutations associated with WD are known (http://www.wilsondisease.med.ualberta.ca/database.asp) 10 . The high prevalence of compound heterozygosity prevents a clear correlation between genotype and phenotype in affected individuals. A large fraction of mutations are missense mutations producing a single amino-acid change in Wilson ATPase ATP7B. ATP7B is a large membrane protein located in the trans-Golgi network (TGN). In normal liver, ATP7B has two functions: (i) it transports copper into the TGN for incorporation into ceruloplasmin and (ii) exports excess copper by sequestering metal in vesicles for subsequent biliary excretion. The second function requires ATP7B trafficking from TGN to endocytic vesicles in response to elevation of intracellular copper concentration.
The ATP7B-mediated transport of copper involves several steps. First, ATP7B binds copper via its cytosolic N-terminal domain and ATP via the nucleotide-binding domain. ATP is then hydrolyzed, and ATP7B becomes transiently phosphorylated at the residue D1027 located in the P-domain (catalytic phosphorylation). Subsequent dephosphorylation releases energy necessary to transfer copper across membrane (transport step) ( Figure 1A,B) . Each of these steps may be affected by WD-causing mutations 11 . The effect could be severe resulting in a Figure 1B ) and tested the intracellular localization for mutants, for which transport activity was observed. The mutants and variants were chosen based on clinical findings (see WD database 10 ) and recent literature; gene variants found in the population with no WD symptoms were also characterized.
Materials and Methods
Reagents and cell lines
All chemicals, unless otherwise specified, were purchased from Sigma (Deisenhofen, Germany 
Generation of Recombinant Baculovirus ATP7B variants
The plasmid encoding the full-length 4.4-kilobase ATP7B cDNA (pFastBacDual-wt-ATP7B) and the catalytically inactive D1027A mutant were previously described 18 and used as a template. The ATP7B mutations were introduced with the QuikChange TM site-directed mutagenesis kit (Stratagene, La Jolla, CA) and appropriate primers (Supplementary Table   1 ). The entire coding sequence of all constructs was verified by automated sequencing.
Expression in Sf9 insect cells and preparation of membrane fractions
Maintenance, infection with recombinant viruses, harvesting of Sf9 insect cells, and isolation of membrane fractions were carried out as described earlier 18, 19 . To obtain a total microsomal fraction, cells from a 50-ml culture were pelleted by centrifugation at 500g (10 min, 4°C) and then resuspended in 5 ml of homogenizing buffer (HB): 25 mM imidazole, pH The expression of wt-and mutant ATP7B was analyzed by separating 50 µg total membrane protein on a 7.5% Laemmli gel 21 followed by Coomassie staining and Western blotting with polyclonal antibody a-ABD (1:20,000) 18, 19 .
Preparation of vesicles for copper transport
Sf9 cells were infected with virus encoding wt-ATP7B, empty vector (mock), or ATP7B
variants and harvested after three days. Cells from a 50 ml culture were pelleted, analyzed by Western analysis using polyclonal antibody a-ABD 18, 19 .
Cu-uptake in vesicles
The transport assay was performed according to Gmaj et al. 23 . After electrophoresis the gels were fixed in 10% acetic acid for 10 min and dried on blotting paper. The dried gels were exposed overnight either to a screen for the Fuji BAS reader (Fuji, Düsseldorf, Germany) or Kodak BioMax MR film (Kodak, Rochester, NY). The photonstimulated-luminescence intensity of bands was quantified using Aida Image Analyzer (Raytest, Straubenhardt, Germany). To test ATP-dependent dephosphorylation, ATP was added after [γ-32 P]ATP phosphorylation to a final concentration of 1 mM at room temperature and incubated for 10 min before the reaction was stopped and samples were processed in the same manner as described above.
Expression and localization of ATP7B variants in HEK 293 T-REx™ cells
Selected mutations (L1083F, R969Q, and A874V) were introduced into a GFP-ATP7B construct (kindly provided by Dr. Ann Hubbard, Johns Hopkins University) using the QuikChange Site Directed Mutagenesis kit and appropriate primers (Supplementary Table   1 Germany).
Protein modeling
The location of the mutations in different functional domains was visualized using available NMR structures for the N-domain 24 , N-terminal Cu-binding unit domain 25 and the A-domain 26 .
The structures of the P-domain where modeled using the ESyPred3D Web Server 1.0 and the crystallographic structures of CopA ATP-binding domain as template (RCSB accession number 2b8e) 27, 28 .
Results
In vitro copper transport assay
We first determined whether an ATP7B-dependent copper transport can be detected in ATP7B-containing microsomal vesicles from Sf9 cells used as a model for TGN vesicles. In the presence of ATP, the addition of 64 Cu resulted in an accumulation of copper in ATP7B-containing vesicles ( Figure 2) ; whereas no transport was observed in vesicles prepared from cells infected with empty virus (mock) (Figure 2A ). To verify that copper accumulation was due to an enzymatically-driven process, we repeated experiments at 4°C. No copper accumulation was observed at 4°C ( Figure 2A ). Orthovanadate (200 µM Na 3 VO 4 ), a general inhibitor of P-type ATPases, significantly inhibited but did not fully eliminate copper uptake ( Figure 2A) . Consequently, to further verify that copper accumulation was due to transport and not simply binding of copper to ATP7B, we analyzed the D1027A mutant of ATP7B, in which catalysis is disrupted but copper binding is preserved. This mutant yielded no copper accumulation in vesicles ( Figure 2B ).
The effect of mutations on copper transport
To determine the effect of mutations on ATP7B transport function, we generated 25 WDassociated variants and three predicted polymorphisms. Substitutions were made within different functional domains to better understand the structure-function relationships ( Figure   1B ). The wt-ATP7B and mutants were expressed in the Sf9 cells under identical conditions.
Western blot analysis illustrated that protein expression was easily detectable for all mutants (Supplementary Figure 1) . In contrast, there was a marked variation in copper transport (Table 1 , Figure 2C ,D, Supplementary Figure 2) . The majority of ATP7B mutants (16 out of total 25) had essentially no activity (less than 5% of wt) or a very low activity (5-10%); the H1069Q mutant (frequently found in Caucasian population) belonged to this latter category ( Figure 2C ). Unexpectedly, a sizeable fraction (8 out of 25) of mutants showed partial transport activity (0.22-0.71 nmol/mg protein at 120 min). These mutants included A874V
(frequently detected in Korean population 29 ) and I857T. Most of the partially active mutants had slower transport rates and accumulated less copper than the wt-ATP7B, except the S406A variant that had a slower rate compared to the wt but with time yielded the same level of copper accumulation in vesicles ( Figure 2C,D) . Only one of the ATP7B mutants, M645R, displayed Cu-uptake (1.18 nmol/mg protein at 120 min) indistinguishable from wt-ATP7B
( Figure 2C ). The predicted non-disease variants (V456L and K832R) also showed reduced transport rates ( Figure 2D ). To further verify that these marked variations in activity were not simply due to differences in ATP7B expression levels, we selected several mutants that had similar transport activity, expressed them in parallel under identical conditions, and quantified ATP7B amounts by densitometry. Supplementary Figure 3 illustrates that a drastically different activity of these mutants is not due to difference in their expression levels.
Effect of mutations on catalytic activity
The loss of copper transport could be either due to disruption of copper transfer across membranes or due to the loss of ATP binding/hydrolysis. To better understand which of the steps is affected, we examined the ability of ATP7B to form a phosphorylated intermediate upon ATP binding ( Figure 3 , Table 1 ). In all A-domain mutants phosphorylation was markedly increased ( Figure 3C ). This result indicated that ATP-binding is unaltered, but the well-known function of the A-domain to facilitate dephosphorylation 11 was inhibited. In contrast, ATP7B variants with mutations in the N-terminal domain ( Figure 3A ), transmembrane domain ( Figure 3B ), the P-or N-domains ( Figure 3D , and E respectively)
showed either normal or reduced phosphorylation. All three ATP7B gene variants not associated with disease showed normal phosphorylation activity ( Figure 3F ). Thus, in our subset of mutants, disruption of ATP binding is not a major defect.
Partial transport activity along with hyperphosphorylation for several mutants suggested that these mutants have altered conformation (or defects in the communication between functional protein domains necessary for optimal protein activity). This conclusion was supported by experiments on dephosphorylation. When hyperphosphorylated mutants were incubated with cold ATP, dephosphorylation was observed for all examined mutants ( Figure   4A ,B). Thus, the hyperphosphorylated mutants are able to perform all the steps of the cycle and the transport defect in these mutants is associated with structural changes affecting rates of the individual step(s).
Expression and localization of functional ATP7B mutants in mammalian cells
The ability of several mutants to hydrolyze ATP and transport copper in vitro suggested that displayed characteristic endoplasmic reticulum (ER) localization, which was confirmed by costaining with the ER marker Calnexin ( Figure 5 ). Both mutants also showed weaker signal intensity compared to wt-ATP7B. Thus, despite the lack of gross misfolding (indicated by the ability to perform key functional reactions in vitro), the structural changes in A874V and L1083F mutants were sufficient to produce apparent destabilization and ER retention. Thus, mislocalization is the major reason for the loss of copper delivery to the TGN by these mutants.
Previous studies reported that the stability and localization of some ATP7B mutants (e.g.
R778L and H1069Q) can be corrected by growing cells at 30°C 17 . Consequently, we tested whether the targeting of A874V and L1083F (which show copper transport activity after being expressed at 27 o C in Sf9 cells (Table 1 The comparison of A874V with the recently characterized G875R variant further illustrates an extremely delicate and precise architecture of the ATP7B molecule 30 . The A874V mutation is located within the flexible loop of the A-domain ( Figure 6A ) and is not expected to markedly alter protein structure. This prediction is consistent with the actual functional properties of the mutant, i.e. its ability to transport copper using ATP hydrolysis. And yet, in cells the lack of precise folding prevents the A874V exit from the ER, thus disrupting copper delivery to the secretory pathway and likely causing WD phenotype. Similar ER retention of G875R (the mutation of a neighboring residue) can be corrected by increasing copper concentration in cells 30 , which facilitates ER exit and proper TGN targeting (and activity). In contrast, treatment with copper does not improve the A874V stability or localization.
Altogether, our studies demonstrate the need for utilizing an arsenal of methods for understanding the phenotype of disease-causing mutation, since individual assays yields only partial and non-overlapping information about ATP7B properties.
It is useful to compare the advantages and disadvantages of various assays and information that can be generated. Yeast complementation assay is an effective way to identify ATP7B mutants, which completely lost their transport activity from those that have some activity left 12 . However, it is difficult to draw more specific conclusions about properties of the WD mutants because it is unknown how much copper transport activity is necessary to allow yeast to grow. Overexpression of mutants with very low activity might be sufficient to allow copper delivery to the TGN and growth. In addition, yeast cells grow at lower temperature (30 o C), which may be sufficient to stabilize proteins that unfold and degrade at 37 o C. For example, H1069Q, which has low copper transport activity and is unstable in mammalian cells 13 complements yeast phenotype 31 Expression in insect cells may underestimate the effects of mutation on protein stability due to lower temperature necessary for growth of insect cells (27°C). However, it provides a marked advantage when detailed mechanistic understanding of functional consequences of mutations is desirable. We found that measurements of catalytic phosphorylation and dephosphorylation of ATP7B mutants expressed in Sf9 cells were the least predictive of the overall functional outcome of mutations as many mutants that showed no transport activity were still able to undergo catalytic phosphorylation. Since the phosphorylation assay is least sensitive, we suggest that the mutants that show no activity in this assay are most severely affected. Indeed, these mutants (G85V, L492S, G1266R, E1046K, and D1222V) show neither catalytic nor transport activity. The marked effect of the last three mutations on ATP hydrolysis is not surprising as they all affect conserved residues in the immediate vicinity to ATP ( Figure 6A ). In contrast, dramatic negative effects of G85V and L492S mutants were unexpected as both residues belong to the regulatory N-terminal domain, which is thought not to be critical for ATP binding and hydrolysis. We hypothesize that these mutants may mediate their effect indirectly through interaction with other functional domains. Because the N-domain interacts with the ATP-binding domain and these interactions affect protein activity 32 , abnormal inter-domain interaction due to mutation may decrease affinity for ATP and/or trap protein in conformation not suitable for ATP hydrolysis.
The transport assay is the most direct way to evaluate ATP7B function. This assay identified several mutants that were transport competent, i.e. could be functional in a cell. Identification of such mutants is particularly important, because they are promising candidates for possible 
Combination of the in vitro and in vivo assays also discriminates between the effects of mutations on protein folding and function. Protein stability in cells is not indicative of function,
because catalytically inactive mutants could be structurally stable, whereas partially active mutants may degrade rapidly, producing a "complete-loss of function" phenotype. Having information on both parameters could be particularly important for future attempts to correct the mutant phenotype by improving protein stability. For example, increasing stability of mutants such as the A874V mutant could be beneficial, because A874V has a significant transport activity. Recent studies using pharmacological folding chaperones 4-phenylbutyrate and curcumin illustrate a possibility of correcting the stability/folding defects of several ATP7B mutants in cells 17 . In contrast, improving stability of other mutants (such as G85V or mutants located in the vicinity of the key functional sites, Figure 6A ) can be without effect since these mutants lack catalytic and transport activity. Lastly, our studies revealed that the non-disease causing changes (V456L and K832R) may nevertheless decrease ATP7B activity. Thus presence of such variants, while by itself no causative, may have a compound effect when found in combination with other mutations and put carriers at disadvantage.
In conclusion, mutations in ATP7B have various effects altering protein expression levels, catalytic and transport activity, as well as intracellular localization ( Figure 6B ). Mutants with a partial preserved transport function may result in later onset of disease or have variable manifestation if their stability and localization is modulated by the metabolic state of cells.
Detailed characterization of ATP7B mutants is likely to contribute to the analysis of genotype-phenotype correlations in WD. TGN46 is a TGN marker; Calnexin is marker for ER. 
